C. Zahonero

EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy

P. Sánchez-Gómez, C. Zahonero, 2014, Cellular and Molecular Life Sciences.

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

M. Pajares, A. Hernández-Laín, P. Sánchez-Gómez, 2015, Molecular Cancer Therapeutics.

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma

P. González-Gómez, M. Garcia‐Fuentes, J. Crecente‐Campo, 2015, Oncotarget.

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.

M. Hagiwara, A. Hernández-Laín, P. Sánchez-Gómez, 2013, The Journal of clinical investigation.

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis

P. Sánchez-Gómez, C. Zahonero, P. Fernández-Martínez, 2015, Molecular & cellular oncology.

Targeting EGFR in Glioblastoma: Molecular Biology and Current Understanding

J. Sepúlveda, C. Zahonero, P. Gomez, 2017 .

EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy

P. Sánchez-Gómez, C. Zahonero, 2014, Cellular and Molecular Life Sciences.